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Abstract Over the past 20 years children have benefited
from major improvements in both technology and clinical
management of dialysis. Morbidity during dialysis ses-
sions has decreased with seizures being exceptional and
hypotensive episodes rare. Pain and discomfort have been
reduced with the use of chronic internal jugular venous
catheters and anesthetic creams for fistula puncture. Non-
invasive technologies to assess patient target dry weight
and access flow can significantly reduce patient morbidity
and health care costs. The development of urea kinetic
modeling enables calculation of the dialysis dose deliv-
ery, Kt/V, and an indirect assessment of the intake. Nu-
tritional assessment and support are of major importance
for the growing child. Even if the validity of these “urea
only” data is questioned, their analysis provides infor-
mation useful for follow-up. Newer machines provide
more precise control of ultrafiltration by volumetric as-
sessment and continuous blood volume monitoring during
dialysis sessions. Buffered bicarbonate solutions are now
standard and more biocompatible synthetic membranes
and specific small size material dialyzers and tubing have
been developed for young infants. More recently, the
concept of “ultrapure” dialysate, i.e. free from microbi-
ological contamination and endotoxins, has developed.
This will enable the use of hemodiafiltration, especially
with the on-line option, which has many theoretical ad-
vantages and should be considered in the case of maxi-
mum/optimum dialysis need. Although the optimum di-
alysis dose requirement for children remains uncertain,
reports of longer duration and/or daily dialysis show they
are more effective for phosphate control than conven-
tional hemodialysis and should be considered at least for
some high-risk patients with cardiovascular impairment.
In children hemodialysis has to be individualized and
viewed as an “integrated therapy” considering their long-
term exposure to chronic renal failure treatment. Dialysis
is seen only as a temporary measure for children com-
pared with renal transplantation because this enables the
best chance of rehabilitation in terms of educational and
psychosocial functioning. In long term chronic dialysis,
however, the highest standards should be applied to these
children to preserve their future “cardiovascular life”
which might include more dialysis time and on-line
hemodiafiltration with synthetic high flux membranes if
we are able to improve on the rather restricted concept of
small-solute urea dialysis clearance.
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The European Paediatric Dialysis Working Group was
established in 1999 by pediatric nephrologists from dif-
ferent European countries with a major interest in dialy-
sis. The group has already published guidelines, mainly
on peritoneal dialysis [1, 2]. Hemodialysis practices for
children have improved over the ensuing 20 years, espe-
cially because of technological developments and the
evolution from “minimum/adequate” to “optimum/maxi-
mum” dialysis prescription [3]. Therefore, new general
recommendations seem necessary.
These guidelines were initiated and discussed at
meetings of the group and refined by e-mail discussion to
develop a consensus of opinion, on the basis of cumula-
tive clinical experience and reported studies. This paper
will discuss the main factors affecting hemodialysis pre-
scription and management in children.
In some European countries hemodialysis (HD) is of-
ten preferred for children over the age of five years [3]. In
contrast, peritoneal dialysis (PD) is offered to the younger
children especially under the age of two years or weigh-
ing less than 10 kg. A multicenter European study has,
however, found that 73% of 189 children were older than
five years when peritoneal dialysis was started [4]. Fac-
tors ranked as first priority for choice of therapy [4] in-
cluded age of the child (30%), parent choice (27%), dis-
tance from unit (14%), patient choice (11%), social con-
dition (7%), and unable to do one mode (6%). Never-
theless important differences appear in the individual
countries. Usually, however, HD is not offered to children
less than 5 years old unless there are important contra-
indications for PD [1]. For older children HD is applied
for drop-outs from the PD program or if there are medical
(rare) or psychosocial (more often) reasons for not per-
forming PD.
Choosing a mode of dialysis, either HD or PD, for a
child requires consideration, among other factors, of the
probable impact of either mode of dialysis on the main-
tenance of residual renal function (RRF), because of its
specific impact on patient outcome. Although there is no
general consensus, peritoneal dialysis has been associated
with less risk of RRF loss [5, 6]. Overall the choice of the
mode of dialysis is just a part of the integrated care
model, each child should be considered for a combined
dialysis-transplantation program.
Provision of adequate vascular access remains the
single greatest obstacle to successful HD, especially in
infants. Unlike in the USA, where patients frequently use
a central catheter for vascular access [7], in Europe an
arteriovenous fistula is the most common vascular access
for chronic/long term dialysis [8]. According to the K-
DOQI guidelines, the percentage of catheters in a dialysis
unit for adults should be less than 10%, although many
pediatric centers do not meet this standard, because of the
difficulty of creating fistulas in smaller children, espe-
cially in children less than 2 years of age.
During the past two decades there have been many
improvements in the technology [3]: bicarbonate used as
buffer in the dialysis solution, volumetrically controlled
ultrafiltration, smaller dialysis lines and synthetic mem-
branes useful even for babies, modeling of ultrafiltration
rate and dialysate composition, on line hemodiafiltration
and the concept of ultrapure dialysate, i.e. sterile and
pyrogen free. Non invasive technologies to assess patient
target dry weight and access flow offer a potential de-
crease in dialysis morbidity and costs [9]. Recently mar-
keted medications to improve anemia, for example ery-
thropo etin even darbepoietin, and iron infusion, con-
tribute to the clinical improvement of the hemodialysis
session [10].
Dialysis adequacy quantification by urea kinetic
modeling enables a more specific approach to dialysis
dosing and indirect assessment of protein intake, despite
the limited value of small-solute clearance [11]. Never-
theless, it has been widely accepted that clinical results
depend at least in part on the dialysis dose delivered [12,
13, 14, 15]. In fact, a single center experience shows the
beneficial impact of longer dialysis duration on clinical
outcome in children [13]. However, it is now becoming
more and more evident that increasing the dialysis dose
when delivered only three times weekly is an unphysio-
logical strategy, self limited by the potential increased
risk of hemodynamic and electrolytic disturbances [16,
17, 18]. In adult care, there is a growing interest in the use
of daily dialysis, because long term experience has shown
good results [16, 17, 18]. In children only a pilot study in
one center supported the positive impact of daily dialysis
in very non-compliant adolescents [19].
In children the hemodialysis prescription should be
individualized. Choice of the mode of hemodialysis
should take into account the presumed waiting time be-
fore kidney transplantation as a “ justification” for the use
of “ the best available” mode having the highest cost and,
conversely, being supported by very limited/preliminary
studies only [13, 19].
The importance of the choice of material used for di-
alysis and its application should not obviate the need for
management of the entire child with ESRF, especially
regarding optimum nutrition [20]. Because dialysis per se
is not able to correct completely the numerous functions
of the kidney lost during ESRF, medications and dietary
recommendations are needed in children on hemodialy-
sis [20]. Recombinant growth hormone is often needed
considering the growth velocity rate of children on
chronic dialysis [3].
Guideline 1: the dialysis unit
– hemodialysis should be delivered in a “pediatric” di-
alysis center with a multidisciplinary support team
which supports individualized and integrated therapy
– nutrition, growth, and educational support are of major
importance
Because of the specific needs of children, hemodialysis
should be delivered at the best, and probably only, in a
1055pediatric dialysis unit [3, 4, 7] This includes the treatment
of adolescents up to the age of 18 years and beyond de-
pending upon their physical and psychological develop-
ment and transition arrangements to adult units [21].
Taking care of a child with ESRF necessitates an engaged
team consisting of doctors, nurses, dietician, psychologist,
school teacher, play therapist, and social worker [22].
This “second family or support team” should be multi-
disciplinary and immediately available to the chronically
ill child, both close and distant enough to stimulate nor-
mal family life, supporting a proper (school) education,
leaving all possibilities open for “full” integration into
society in the future.
Hemodialysis, in contrast with peritoneal dialysis, is
usually performed in an hospital setting, with a frequency
of three times per week for most patients. This frequency
may be increased to address the specific needs of babies
and/or adolescents requiring “more dialysis” [3, 13, 19].
Guideline 2: water quality
– adequate in terms of biochemical composition
– free from microbiological contamination
The dialysis machine needs water for dialysate production
adequate in terms of biochemical composition and free
from microbiological contamination, i.e. germs and en-
dotoxins (Table 1). Water purification depends on the
disposable water quality. Usually filtration with charcoal
and the small sieving coefficient associated with reverse
osmosis produces water for dialysis in accordance with
the recommendations [23] (Table 2). Currently, all new
dialysis machines have the ability to filter the dialysate
through a high flux membrane, which increases micro-
biological purity.
In hemodiafiltration using an on-line technique [24,
25] with direct production from the dialysate of the he-
mofiltration substitution fluid, the dialysate benefits from
double ultrafiltration, producing an ultrapure dialysate
which is sterile and endotoxin free, at least at detectable
levels. This ultrapure dialysate should limit the risks re-
lated to microbiological contamination, i.e. inflammatory
process induction with both acute and chronic conse-
quences [23]. This level of ultrapure dialysate is also re-
quired for synthetic high-flux membrane use even or es-
pecially when used in a conventional hemodialysis mode.
Decontamination or sterilization by chemical agents or by
heating should be performed in line with water, before
final dialysate production by the dialysis machine, by
filtration and osmosis installation and water distribution,
without any break between sterilization and final dialy-
sate. Quality control of the water for the dialysate should
be performed regularly with regard to chemical compo-
sition (at least once per year), and final dialysate purity
should be assessed with regard to bacteria and endotoxins
(more regularly, depending in part on the mode of dial-
ysis, weekly for high-flux membrane use) (Table 2) [23].
Guideline 3: the dialysis machine
– volumetric ultrafiltration control
– option for both single and double-needle dialysis
In the last decade numerous innovations in equipment
have been developed by different manufacturers [3]. But
the relevance to child outcome remains unknown, because
of the absence of sufficient controlled study results.
Nevertheless the following innovations seem essential:
dialysate production by double dilution pumps using
volumetric ultrafiltration control and blood pumps with
double pumps available for single-needle dialysis.
Other “high-tech” innovations only deserve mention
because of their limited application in “expert” centers:
individual modeling of the dialysis session with moni-
toring of ultrafiltration and dialysate solute concentration
(i.e. sodium, bicarbonate); polyvalency machine which
enables not only conventional dialysis but also hemofil-
tration and hemodiafiltration providing the highest stan-
dard in terms of tolerance and efficiency [24, 25]. Newer
dialysis machines provide monitoring of hematocrit
variation as a major promising innovation [9, 26] and
direct urea kinetic monitoring [27]. There is a restricted
offer for blood thermal monitoring to avoid loss of
calories to the dialysate or to prescribe cooled dialy-
sate [28].
Table 1 Water contaminants and associated complications
a
Dissolved organic material Complications
Contaminants:
- Pesticides, herbicides No documentation during dialysis
- Chloramines, chlorine
compounds
Severe hemolytic anemia
Bacteria and pyrogens:
- Bacteria Bacteremia or septicemia
Fever, chills, shaking
Hypotension and death
- Pyrogens Pyrogenic reaction-fever
Chills, uncontrollable
Shaking, vomiting, hypotension
a Not exhaustive
Table 2 Definitions of water
and dialysate quality (levels
given as an upper limit for
water-quality definition [70])
Bacterial growth (cfu mL
 1) Endotoxin (EU mL
 1) Cytokine-induction
AAMI, water 200 5 +
European pharmacopoeia
Regular water 100 0.25 +
Ultra-pure 0.01 0.03 –
Sterile 10
 6 0.03  
1056All these innovations enable individualized hemodi-
alysis for the children, but their regular application should
take into consideration the balance between the expected
benefits and the costs.
Guideline 4: blood lines
– available in infants/babies size
– biocompatible material
A range of blood lines are available for dialysis of babies
to dialysis of the largest adolescent. They should be
considered for their biocompatibility, type of sterilization
(ethylene oxide-free), and the blood volume required [3].
Guideline 5: principles of blood purification
– small solute clearance and more, from diffusion pro-
cess (urea) to convection (other uremic toxins “middle
molecules”) mass transport
– hemodiafiltration is an option to consider to obtain
“maximum” dialysis efficiency
Uremic toxin extraction in dialysis [3, 24] is related to a
combination of the diffusion process and convection mass
transport (Table 3). In hemodialysis (HD), blood purifi-
cation depends mostly on a diffusion process secondary to
a concentration gradient, which ensures the best elimi-
nation of small molecules (urea). HD clearance (KHD)
correlates directly with blood flow rate. In hemofiltration
(HF), uremic toxin extraction is mostly dependent on
convection mass transport secondary to a pressure gradi-
ent, which optimizes the elimination of both low and
middle-molecular-weight compounds. HF clearance
(KHF) directly correlates with ultrafiltration flow rate
which is limited by the blood flow rate. In the post di-
lution mode, i.e. replacement fluid in the venous line
chamber located after the dialyzer membrane, maximum
filtrate flow rate is less than half the blood flow rate; it is
usually one third, to limit the risks of excessive hemo-
concentration. In the predilution mode, i.e. replacement
fluid perfusion in the arterial line chamber, which is sit-
uated before the dialyzer membrane, maximum filtrate
flow rate should be two thirds of or equal to the blood
flow rate. Hemodiafiltration (HDF) combines HD and HF
simultaneously, which enables blood purification by both
a diffusive process and convective mass transport. HDF
clearance (KHDF) in post-dilution mode is measured by
use of the Granger formula [24]:
KHDF ¼ KHD 1  QUF   S=Qb ðÞ þ KHF
On replacement of QUF S by KHF and Qb by Kmax
(maximum achieved clearance) the formula for KHDF
becomes:
KHDF ¼ KHD þ KHF  
KHD   KHF
Kmax
Thus it is clear that in terms of blood purification KHDF
enhances the clearance of a uremic toxin if HF or HD
clearances are lower than the Kmax (equal to the blood
flow rate). HDF with a highly permeable membrane is as
efficient as HD for low-molecular-weight compounds, but
is more efficient than HF for low-molecular-weight
compounds [29]. Moreover, HDF, besides its blood pu-
rification efficiency, is associated with a lower intradia-
lytic morbidity rate [30, 31], as is HF [3]. On-line
HDF [24, 25], in which filtered dialysate free of toxins
and pyrogens is used as replacement fluid, enables use of
an elevated convection fluid rate, especially in predilution
mode, and facilitates a dialysis dose increase without a
cost increase. The use of ultrapure dialysate, i.e. sterile
and pyrogen free, as used for on-line HDF dialysate
should reduce the diseases possibly associated with
chronic inflammation related to contaminated dialy-
sate [23], e.g. b2 microglobulin amyloidosis, hyperca-
tabolism with loss of lean body mass, decreased growth
rate, fibrosis and cardiovascular diseases. A high flux
membrane [32], with an elevated ultrafiltration coefficient
of permeability enabling backfiltration from the dialysate
to the blood compartment, which is called retrofiltration,
increases these risks, especially with contaminated dial-
ysate [23].
Guideline 6: extracorporeal blood access
and circulation
– fistula vascular access is preferred for long-term
chronic hemodialysis
– in young children, less than 15 kg, the time needed to
develop a fistula before it can be used could be some
months
– the double-needle technique is the standard, but single
needle with double pump system is an alternative
Table 3 Dialyzer membrane permeability: diffusion and convec-
tion
Diffusion process Convection mass transport
Membrane area Ultrafiltrate flow (QUF)
Mass-transport coefficient Hydraulic permeability
Concentration gradient Transmembrane pressure
(TMP; mmHg)
Blood flow extraction
coefficient
Membrane area
KHD ¼ Qb  
ci co
ci Sieving coefficient (S)*
ci and co are inlet and
outlet solute concentrations
Molecular permeability
*S ¼
2CUF
ciþco
CUF is the ultrafiltrate solute
concentration
KHF ¼ QUF   S (postdilution)
KHF ¼
QB QUF
QB QUF   S (predilution)
KHD is hemodialysis clearance and KHF is hemofiltration clearance
1057– a single lumen catheter with clamps offers for small
children an acceptable compromise between a very
low extracorporeal blood volume and valuable dialytic
efficacy
– total extracorporeal blood volume (needles, tubing and
dialyzer) should, approximately, be less than 10% of
patient total blood volume
– anticoagulation in the extracorporeal circuit is
achieved either with conventional heparin or with low-
molecular-weight heparin
– an extracorporeal blood flow rate (QB) of 150–
200 mL min
 1 m
 2 or 5–7 mL min
 1 kg
 1 is often
sufficient
The success of chronic hemodialysis depends on good
vascular access: internal arteriovenous fistulae (AVF),
shunt (AVS), graft (AVG) or central venous catheter. The
type of access used is variable depending on factors in
different units and countries, for example surgical expe-
rience, patient age and size, the time available before
dialysis must be started, and the presumed waiting time
before transplantation. Patient choice plays a major part,
especially with adolescents.
A catheter is more commonly used in the USA than in
Europe [7, 8]. A catheter can be a primary access par-
ticularly in acute renal failure or chronic renal failure with
acute presentation, in small children and in the case of a
presumed short period on chronic hemodialysis. Internal
jugular vein catheter access is superior to subclavian vein;
it admittedly preserves the future arteriovenous fistula
implantation on the arm. Femoral catheter access should
be used only for “rescue and transient” access if intensive
care is needed: it is easy to perform but with a higher risk
of infection and thrombosis. A double lumen cuffed
catheter, at least 8 French, is mostly preferred for children
and has been reported to have a survival rate as high as 60
to 85% in one year [33], or as low as 30% [34]. Never-
theless in small infants a single lumen catheter used with
the alternative clamps technique offers an acceptable
compromise between recirculation and both the amount of
extracorporeal blood volume and the achieved blood
flow [35]. Thrombosis, a major cause of catheter failure,
is reported to be between 9 and 46% [34]. Thrombosis
causing poor flow can be corrected to salvage the catheter
by different methods: catheter replacement over guide-
wire, systemic oral anticoagulation and local urokinase or
tissue plasminogen activator instillation [36]. Loss of
catheter access related to infection has decreased during
the last decade; the aggressive use of antibiotics and
perhaps antibiotic lock therapy, although not universally
accepted, account for this lower rate of infection related
catheter loss [34, 36, 37].
Microsurgery enables creation of a functional AVF at
the wrist in most children, even small ones [8] but only a
few surgeons are trained for vascular microsurgery, which
therefore is rarely used. Creation of a fistula at the elbow
is a second-choice vascular access. With a non functional
cephalic vein, a basilic vein transposition, i.e. superfi-
cialization, is possible [38]. Synthetic grafts should be
reserved for children who have exhausted autologous
veins and should be used in children only very rarely. For
all these reasons preoperative evaluation of the vessels to
determine the correct choice of vein before the operation
is mandatory. The non-dominant arm should be regarded
as first choice of fistula implantation. The survival rate for
a AVF is higher than the survival rate for a catheter, with
more than two thirds of the children having a functioning
AVF at four years [8]. With a basilic vein superficial-
ization the fistula should not be used before full healing (2
to 6 weeks) to avoid a dissecting hematoma. Otherwise
the time needed for venous development before use de-
pends on the age of the patient and the place of the AVF
(distal or proximal). In small children this period of time
is often a delay of months. Before surgery it is essential to
avoid venopuncture of the selected arm in the weeks
before AVF creation. It is of interest to protect the
dominant arm from the beginning of taking care of a child
with “chronic dialysis risk” to enable, if necessary, im-
plantation of a fistula. Such venoprotection should not be
forgotten for peritoneal dialysis children, even babies/in-
fants. For a period of time before surgery, especially for
small children, [8] dilatation of the veins by immersion of
the forearm in hot water is advantageous, a maneuver
enhanced by placement of a tourniquet. A proximal AVF
with a high blood flow, usually close to 1000 mL
min
 1 m
 2 , is a risk factor for cardiac failure. Never-
theless, the major complication is thrombosis, consequent
to local stenosis. Therefore, follow up of the access flow
is essential, on the one hand clinically: auscultation (the
sound of the AVF is maximum at the surgical site and
decreases with distance from the fistulae), observa-
tion (elevation of the forearm should induce emptying of
the previous dilated veins, and on the other hand by
Doppler ultrasound or vascular access flow monitor-
ing [9]. Application of regular access flow monitoring can
be used to detect vascular stenosis before complete AVF
thrombosis [9]. But it should be remembered that
“Transonic” access flow monitoring can only be per-
formed with double-pump dialysis and is not available for
pediatric-sized blood lines.
The extracorporeal blood flow rate is achieved through
venous puncture, most often via two needles, one for
blood aspiration called the arterial needle, one for venous
reinjection called the venous needle. The distance be-
tween the needles should be sufficient to limit recircula-
tion, which is best prevented by opposite orientation of
the needles: the arterial one toward the fistula, the venous
one in the opposite direction. Usually the needle size is
17-gauge at initiation of dialysis; thereafter considering
patient need and fistula development 16 or 14-gauge
needles, particularly in adolescents, can be used to
achieve a sufficiently high blood flow rate. Pain related to
the puncture should be prevented by anesthetic cream
(Emla or Amelop); this advance is important for both the
children and nurses [39].
An extracorporeal blood flow rate (QB) of 150–
200 mL min
 1 m
 2 , 5–7 mL min
 1 kg
 1, is often suffi-
cient to achieve the targeted goals with double needle
1058dialysis; in small children QB is determined using body
weight (BW, kg): (BW+10) 2.5=QB (mL min
 1). The
arterial blood aspiration pressure should be monitored if
possible and kept between 150–200 mmHg to limit en-
dothelial trauma.
For single-needle dialysis in children the highest blood
flow rate is obtained with a double pump system (venous
flow higher than arterial flow) monitored by the pressure,
system called time pressure regulation. The risk of re-
circulation is important with the latter; some machines
limit this risk more than others, especially with the ad-
dition of clamps. Conversely for small infants a single
lumen catheter used with the alternative clamps technique
is an acceptable compromise between recirculation and
both the extracorporeal blood volume and the achieved
blood flow [35].
The total extracorporeal blood volume (needles, tub-
ing, and dialyzer) should preferably be less than 10 % of
patient total blood volume. This is essential for small
children; however, the relative normal hemoglobin level
obtained with erythropo etin therapy enables this volume
to be exceeded slightly without significant hypotension at
the end of dialysis session when the patient reaches dry
body weight. Nevertheless, it should be kept in mind that
the higher the extracorporeal blood volume, the higher the
volume of returned fluid, which will load the patient with
fluid at the end of the dialysis session. (In very small
children the substitution by air may be necessary to limit
blood loss on one side and high substitution volume on
the other side, but is very dangerous and should be strictly
monitored.) System priming with saline, albumin, and
sometimes blood should be applied in the first dialysis
sessions with babies or small infants.
Anticoagulation of the extracorporeal blood volume is
performed either by use of conventional, heparin with
continuous infusion of 20 to 30 IU kg
 1 h
 1, or with low-
molecular-weight heparin at 1 mg kg
 1 as a bolus at the
beginning of the dialysis session. If the hematocrit is over
35%, the risk of clotting is increased. Regional citrate
anticoagulation is sometimes used especially when acute
dialysis is needed [2]. Predilution treatment, feasible in
either hemofiltration or hemodiafiltration, reduces the risk
of clotting and even enables dialysis without anticoagu-
lation in some circumstances. In the presence of throm-
bopenia heparin-toxicity is to be suspected.
The venous blood line has a pediatric size air-trap
chamber to limit extracorporeal blood volume. The dial-
ysis membrane is protected by an arterial chamber of
expansion which in small children is often not incorpo-
rated in the line to reduce the extracorporeal blood vol-
ume. Prevention or treatment of ethylene oxide allergy is
possible by using steam sterilization of needles, lines, and
membranes; this is becoming the preferred option
throughout Europe.
Guideline 7: which dialyzer membrane to “choose”
– synthetic membrane, low flux, capillary configuration
– high-flux membrane use requires use of ultrapure di-
alysate
– removal of urea and other uremic toxins dialytic
should be considered, especially in chronic, long-term
dialysis
Three general types of membrane are available at pres-
ent [32]: unmodified cellulose (low flux and so-called
bioincompatible membranes), modified/regenerated cel-
lulose (low flux or high flux; so-called relatively bio-
compatible), synthetic (low flux or high flux; so called
relatively biocompatible).
The choice of a dialyzer membrane should take into
account the following (Table 4):
– the biocompatibility of the material towards leucocytes
and complement activation
– the blood volume priming requirement, which is
membrane area-related
– the permeability, determined in the most simple way
by two characteristics:
– hydraulic permeability (CUF) measured in mL per
mmHg of transmembrane pressure achieved per
hour, i.e. either low permeability, CUF under
5 mL mmHg
 1 h
 1 (low-flux membrane), and high
permeability, CUF over 15 to 20 mL mmHg
 1 h
 1
(high-flux membrane)
– molecular permeability determined at least by the
molecular weight of the molecule considered, usually
between 0.8 and 0.9 for urea and lower for the other
uremic toxins with a cut off of zero for albumin. In
practice this cut off is often under a molecular weight
of 20,000 Daltons. The profile of this molecular per-
meability [40, 41] is a specific characteristic of each
manufactured dialysis membrane. Highly permeable
membranes give the theoretical potential for middle-
molecular-weight (Babb theory; 500 to 2,000 Daltons)
uremic toxins being removed during dialysis. In adult
dialysis patients the clinical benefits of improved re-
moval of middle molecules by high flux, large pore,
biocompatible membranes, more or less established,
Table 4 Dialyzer membranes:
practical parameters of choice
- Type of membrane: biocompatibility toward complement system
- Initial blood volume needed, i.e. area-related, quality of restitution
- Molecular permeability: maximum clearance for urea and the other uremic toxins, e.g. phosphate,
related to potential patient osmotic risk
- Hydraulic permeability: possibility of use for HF or HDF procedure, but related to back filtration risk,
high flux membranes need ultrapure dialysate
- Adsorption capacity on to the membrane (a characteristic of synthetic membranes)
- Cost
1059are [41]: reduction of uremia related amyloidosis,
maintenance or residual renal function, and reduction
of inflammation, malnutrition, anemia, dyslipidemia,
and mortality.
– The absorption capacity on to the membrane, (IL1,
TNF, IL6, b2 microglobulin):a characteristic of syn-
thetic membranes
For conventional dialysis low-flux membranes are suit-
able, but to achieve hemofiltration or hemodiafiltration
high-flux membranes are necessary. The higher the hy-
draulic permeability, the higher is the backfiltration risk;
this process could be limited both by permanent con-
vective flow from the blood compartment to the dialysate
compartment, as ultrafiltration (HF, HDF, or at least
weight loss) and by use of ultrapure dialysate. Synthetic
membranes seem the best theoretical choice but clinical
justification of the relatively higher cost is uncertain [32].
Justification for use of high-flux synthetic membranes, as
used in on-line HDF, remains a matter of debate for
children on dialysis for short periods only while waiting
for their kidney transplant.
– Reuse of the membrane is not applied in practice for
children.
Guideline 8: the dialysate
– bicarbonate buffered,
– low calcium level (1.25 mmol L
 1) becomes the
standard,
– glucose concentration at physiological level,
– dialysate quality control (germs and endotoxins) is
required
The dialysate is prepared as a dilution of concentrate with
water, ideally with ultrapure water. The composition of
the dialysate has changed over the last two decades [42].
Acetate as buffer has been replaced by bicarbonate, with
the development of machines with two separate dilution
pumps, one for bicarbonate concentrate free from calci-
um, often as a powder, and one for the acid concentrate
containing residual levels of acetate and the electrolytes
(Na, K, Cl, Ca). The current use of oral calcium carbonate
as a phosphate binder has mandated the need to decrease
the calcium concentration of the dialysate, usually at a
low rate, 1.25 mmol L
 1 Ca
2+, less often at a normal rate,
1.5 mmol L
 1, avoiding the “historically” high level of
1.75 mmol L
 1 Ca
2+. In fact, the use of calcium carbonate
combined with a high concentration of calcium in the
dialysate, often led to an elevated Ca P serum product,
compared with the current recommendation of a product
less than 5 mmol
2 m
 2 (60 mg
2 dL
 2) [43, 44]. This Ca P
serum product seems to be an important factor implicated
in the vascular calcifications seen in the dialyzed pa-
tients [43], affecting even the dialyzed children [44, 45].
The need for glucose in the dialysate is of importance [46]
and should be near the physiological concentration.
Higher glucose concentrations or the introduction of
parenteral feeding during dialysis will drive the potassium
into the cells, leading to ineffective potassium-extrac-
tion [41].
Potassium-free dialysate is rarely used because of the
theoretical risk of hypokalemia [42]. Therefore “low” (1–
1.5 mmol L
 1), “normal” (2–2.5 mmol L
 1), and “high”
(3–3.5 mmol L
 1) potassium dialysate are available en-
abling individual adaptation and prevention of the aryth-
mogenic potential of dialysis [42]. Nevertheless special
attention should be devoted to avoiding any confusion
among the “potassium charged” dialysates. Sodium con-
centrations have increased from the previous classical
level of 132 mmol L
 1 to a more physiological level of
138 to 144 mmol L
 1. Newer machine capabilities enable
dialysate profiles to change during a dialysis with respect
to sodium and ultrafiltrate profiles [47, 48] to increase
tolerated weight loss; and bicarbonate profiles [49], to
enhance phosphate removal. Intermittent ultrafiltration
rates, enabling better plasma refilling is the most common
profile used. Similarly, the dialysate flow rate can be
adapted to need, usually in the range 300 to
800 mL min
 1. In general practice, 500 mL min
 1 is used.
The dialysate flow is usually in the opposite direction of
the blood flow, separated by the membrane of the dia-
lyzer. Dialytic thermal exchanges seem of importance
especially for babies and/or high-flow dialysate use,
leading to a risk of patient hypothermia. Control of
thermal exchanges during a dialysis session is therefore
available on a new machine [3, 28].
Guideline 9: post-dialytic dry weight assessment
and adjustment
– particularly difficult to define in growing children
– no “unique” optimum method, importance of a clinical
“pediatric” experience
– need for regular assessment in a growing child
– close collaboration with pediatric renal dietician
Patient dry weight is defined as the weight at the termi-
nation of a regular dialysis session, below which the pa-
tient will become symptomatically hypotensive. Incorrect
estimation of dry weight will lead either to chronic fluid
overload or chronic dehydration. Estimation of dry weight
is particularly difficult in children for many reasons. First,
the hypotensive tendency during a dialysis session is
multifactorial and not only related to the ultrafiltration
rate but also to the plasma refilling rate capacity [47, 48].
Second, body composition, i.e. total body water ratio to
total body mass, is variable with age, especially during
infancy and puberty. In infants and in adolescents dry
weight must be assessed almost monthly to follow rapid
body composition changes during a rapid growth period.
This is also important under anabolic conditions such as
with growth hormone treatment, and conversely under
1060catabolic conditions such as the ill child with intercurrent
infections or reduced food intake.
Clinical criteria used to assess hydration status are
important but not always reliable. Therefore, different
approaches have been proposed: assessment of total body
water by bioelectrical impedance analysis [50], continu-
ous measurement of hematocrit variations by non-inva-
sive methods during dialysis [9, 26], plasma atrial natri-
uretic peptide or cyclic guanosine monophosphate deter-
mination [51], and, last, by echography of the inferior
vena cava (IVC) [52, 53, 54, 55]. Measurement of the
diameter of the IVC (IVCD) by ultrasound, expressed as
an index to body surface-area in mm m
 2, and the de-
crease on deep inspiration, called the collapse index, ex-
pressed as a percentage (%) seems to be an accurate non-
invasive method easily performed serially. An IVCD
between 8.0 and 11.5 mm m
 2 and a collapse index be-
tween 40 and 75 % is considered as representing nor-
movolemia [52, 53, 54, 55]. However, unlike body im-
pedance, interstitial volume and sodium balance are not
reflected by IVCD [55]. In fact all these approaches have
to be balanced by clinical judgment and experience and
combined with nutritional support.
Achievement of dry weight during ultrafiltration is
associated with a drop of the hematocrite level. Ultrafil-
tration is well tolerated until a certain level of decrease of
initial hematocrite, called “crash hematocrite” a patient
individual characteristic, usually over 10% blood volume
reduction over a 3-h session [56]. If the hematocrite curve
is flat over time during a dialysis session, the patient
could be considered as being over his optimum dry
weight [9, 56]. In practice, monitoring of hematocrit (or
blood volume) and guided ultrafiltration should avoid
both fluid overload and hypotensive “crash hematocrit”
and consequently approach more precisely the patient dry
weight [9, 56].
Guideline 10: urea dialytic kinetic, dialysis dose,
and protein intake assessment (nutrition)
Urea kinetic modeling (UKM) has been widely accepted
as a method for dialysis dose assessment despite its lim-
ited value as a unique measure of dialysis adequacy. Does
small solute clearance really matter? [11]. In adult pa-
tients the HEMO study suggested that increasing urea
clearance above currently accepted target ranges does not
lead to improved patient outcome [11]. Although urea per
se is not toxic in concentrations normally encountered in
dialysis patients, it may serve as a marker of unknown
toxins of uremia, some of which are called “middle-mo-
lecular-weight” uremic toxins [11, 41].
UKM facilitates identification of underdialyzed pa-
tients and recognition of dietary compliance. The mea-
sures most widely used to gauge dialyzer treatment are
Kt/V, that is dialyzer urea clearance (K) multiplied by
duration (t) of the dialysis session and divided by urea
volume (V) of distribution, and the normalized protein
catabolic rate (nPCR) [57, 58, 59]. Urea dialytic reduction
rate (URR) is derived from the pre and post-dialysis se-
rum urea values and quantitates urea removal by dialysis.
URR expressed as the ratio post/pre should be at least
equal to or lower than 0.35 and when expressed as the
difference between pre and post-urea, divided by the
predialysis value, should at least equal to or higher than
0.60 [60]. URR is proportional to dialysis efficiency, and
thus to urea dialytic clearance. URR is inversely propor-
tional to the urea refilling rate of the blood compartment
and the extracellular space (EC) from the intracellular
space (IC), called the transcellular urea mass transfer
coefficient (Kie). URR is also correlated with the amount
of urea dialytic removal (Kt) compared to the amount of
urea body content (V) and thus to Kt/V. Usually urea di-
alytic clearance in children is low in comparison with the
high Kie which is between 200 to 1000 mL min
 1 (6 to
12 mL min
 1 kg
 1 BW) [58, 61]. Nevertheless, after di-
alysis the concentration of urea in plasma increases
rapidly in an initial period, usually until 60 min post-
dialysis [62]. This postdialytic urea rebound (PDUR) is a
multifactorial event [63, 64]. Vascular access and car-
diopulmonary recirculation occurs within the first 2 to
3 min of discontinuing hemodialysis and account for 60 to
70% of total PDUR. Subsequently, tissue rebound occurs,
because of intercompartmental, i.e. IC versus EC, urea
dysequilibrium at the end of the dialysis session and tissue
re-equilibration which is usually complete within one
hour postdialysis, reaching the equilibrated postdialytic
plasma urea concentration. For highly diffusible sub-
stances such as urea, distribution in total body water
(TBW) seems to be limited by cardiovascular flow rather
than diffusion [64]. The apparent IC–EC two-pool model
should perhaps be the result of a regional blood flow
distribution system in which approximately 80% of TBW
(and thereby urea) is located in muscle, bone, and skin,
with organs receiving only 20 to 30% of the cardiac
output, i.e. low-flow system. The remaining organs con-
tain only 20% of TBW (hence urea) but receive 70–80%
of the cardiac output, high-flow system. One would ex-
pect the urea concentration in these organs to fall quite
rapidly during dialysis. This flow system, and the vascular
resistance model could explain the great variability of the
PDUR among patients for which the IC–EC two-pool
model is not accurate. Do some patients have thicker cell
walls than others? By contrast the possible causes of
vascular resistance variability, i.e. hypovolemia, hyper-
tension, heart failure, hematocrit, alkalosis or acidosis,
low-temperature dialysate, can explain PDUR variability.
The URR variability could also be explained by vascular
resistance changes over the dialysis session, at least for
urea [64].
Kt/V calculation based on a single pool urea model
neglects compartmental urea distribution in the body,
hence PDUR, resulting in overestimation of actual Kt/V.
Therefore, a two pool model should be applied, using
instead of the urea plasma concentration at the end of the
dialysis, the equilibrated urea, i.e. 60 min postdialysis [65,
66]. Other improvements from the initial formula are
proposed to provide a more accurate Kt/V calculation:
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alysis session (0.008td), leading to the Daugirdas and
Schwartz formula proposed in 1994 [60]:
Kt=V ¼ logn
Cpre
Ceq
  0:008 td  
UF
BW

where td is the dialysis time (h), Cpre and Ceq are, re-
spectively, the predialysis and equilibrated postdialysis
urea concentrations, and UF/BW is the ultrafiltrate-to-
body weight ratio (L kg
 1)
The predialysis blood sample should be taken from the
arterial line, before any rinsing. Because of the practical
difficulty in obtaining the postdialysis equilibrated urea
sample 60 min after the end of the dialysis, different in-
dices have been proposed to estimate Ceq, for example
using a 6 min [67] or a 15 min [68, 69] post treatment
sample. The most important rule of the urea end dialysis
sample should be the use of the “stop dialysate flow
method” [67], measuring urea 6 min after angio access
was removed and cardiopulmonary recirculation com-
pleted.
The other major cause of error for the Kt/V calculation
is determination of V. The V, hence the TBW, could be
calculated from a formula (Table 5) [71] or determined by
bioimpedance measurements [50].
Guideline 11: dialysis dose and outcome
– only “small solute urea clearance” prescription?
– a minimum Kt/V urea level of 1.2–1.4 is thought to be
desirable; adequacy tests should be performed monthly
– dialysis and residual renal small-solute clearance are
not equivalent
– dialysis prescription should be adequate before being
optimum, not only a “urea dialysis dose”
Although the optimum level of Kt/V required is matter of
debate, a minimum Kt/V level of 1.2–1.4 is now thought
to be desirable [11]. Overall, this Kt/V as an index of
dialysis dose should only be analyzed in comparison with
the nPCR, hence the diet, protein and caloric intake
(Fig. 1). Because of the mathematical relationship be-
tween Kt/V and nPCR [72, 73] the real impact of these
variables for a given patient would determine the therapy
necessary for a patient to achieve an “urea dialysis dose”.
Nevertheless increasing dialysis dose seems to have a
direct impact on nutrition [74] and the combination of
increased dialysis dose and adequate nutrition can pro-
mote normal growth in children treated with long-term
hemodialysis [75]. Therefore malnutrition should be
avoided [76] by using a diet survey, anthropometric
measurements, and perhaps IGF1 determination [77].
Does small solute clearance, i.e. urea, really mat-
ter? [11]. Because of the limited number of children on
chronic dialysis the relationship between optimum urea
dialysis dose and patient outcome will be “difficult” to
establish. It is, however, known that blood purification,
dialysis and residual renal small solute clearance, are not
equivalent [11, 78] giving more importance to other
uremic toxins, whose removal is enhanced using high-flux
dialyzer membranes with on-line hemodiafiltration [3, 24,
32, 41].
Even if the pediatric data only seem to be unique
center experiences, the case for a greater urea dialysis
dose [12] could be correlated with both growth rate en-
hancement [12, 13, 19, 78] and improved cardiac func-
tion [14, 19]. The duration of each hemodialysis session is
also matter of debate, long duration being able to induce
regression of left ventricular hypertrophy in adult pa-
tients [16] and being able in children [13] to promote
growth and well being. In the same way daily dialysis
seems related to better clinical results both in adults [17,
18, 77, 79] and in adolescents [19].
Dialysis prescription should be adequate before being
optimum (Table 6) [80]. In long term chronic dialyzed
children the individualized prescription should consider
all the available new strategies to fully preserve at the best
“the life chances” [13, 14, 19].
Guideline 12: the dialysis session, prescription,
and monitoring
– individual prescription is required: babies/infants/
children specificities
– assessment and adjustment is needed regularly in
small/growing children
– psychological preparation of the child and his family is
needed, pain prevention is essential
The first dialysis session is of importance to induce child
and parent confidence, therefore appropriate preparation
is needed. The site of the puncture of the fistula, most
Table 5 Formulas enabling calculation of the volume of distribu-
tion of urea in liters (total body water) using height, weight, sex and
age (from Ref. [67])
Boys: Ht<132.7 cm V=1.927+0.465/BW (kg)+0.0045/ht (cm)
Ht>132.7 cm V= 21.1933+0.406/BW (kg)+0.209/ht
(cm)
Girls: Ht<110.8 cm V=0.076+0.507/BW (kg)+0.013/ht (cm)
Ht>110.8 cm V=-10.313+0.252/BW (kg)+0.154/ht (cm)
Fig. 1 Dialysis prescription balance
1062often with a double needle, size gauge 17, is carefully
chosen and determined so that the needles are sufficiently
separated to limit recirculation. Pain prevention is es-
sential by application of a xylocaine ointment (Emla) one
hour before needle insertion [39]. Psychological prepa-
ration of the child and family is also needed to limit
“anxious stress” [22]. An aseptic procedure is essential.
The extracorporeal circulation is adapted to the level of
arterial aspiration pressure if measurable by the machine
to prevent endothelial vascular trauma (not less than
 150 mmHg). The venous return pressure should not be
more than +200 mmHg to prevent endothelial vascular
trauma.
During the first dialysis session, the blood flow rate is
maintained at a low level to prevent the dysequilibrium
syndrome secondary to too efficient solute removal dur-
ing this first session. Therefore, the blood flow rate should
be approximately 3 mL kg
 1 BW (or 90 mL m
 2), or even
less, so that urea clearance will be less than
3 mL min
 1 kg
 1 BW, which is usually well tolerated
even in small children and limits the development of the
dysequilibrium syndrome. The duration of the first dial-
ysis session should be short, no more than 3 h, or adapted
to the ultrafiltration need. The dysequilibrium syndrome
is most often only symptomatic after one to two hours of
dialysis, with variable symptoms such as headache or
seizure, vomiting, fatigue, sleepiness, or a hypertensive
tendency with a narrow range between systolic and dia-
stolic pressure values. If needed, mannitol infusion
(1 g kg
 1 BW over 1 to 2 h during dialysis) is effective in
preventing the syndrome. Symptoms usually disappear a
few hours after the end of the dialysis.
The extracorporeal blood flow rate, the duration of the
session, and the number of sessions a week is progres-
sively increased to individual patient need. Usually a
blood flow rate of 150 to 200 mL min
 1 m
 2 and three
sessions per week for 3 to 4 h per session achieve the
minimum target prescription of 1.2 to 1.4 Kt/V [11].
The duration of a dialysis session is often prescribed to
reach the anticipated dry weight at the end of the session.
The total amount and the rate of ultrafiltration needed
must be tolerable. A weight loss per hour of 1.5 to 2% of
the BW is standard [3, 80] and most often well tolerated.
Intermittent ultrafiltration with bicarbonate buffered di-
alysate which is not too warm (so called “cooled dialy-
sate”), a normal “high” level of sodium (140 to
144 mmol L
 1), which is not more than the normal con-
centration of sodium per liter plasma water, a normal
hematocrit over 30% and optimally near 35% but not
higher [78], and a mode of dialysis based on hemofiltra-
tion, i.e. (optimally HDF) are some of the major “tricks”
used to enhance ultrafiltration tolerance [3, 48]. Intoler-
ance of weight loss usually becomes symptomatic at the
end of the dialysis session, when the patient is near his dry
weight. Continuous blood volume monitoring during the
session should become a real clinical support to enable
optimum ultrafiltration tolerance (notion of crash hemat-
ocrit) [26, 56]. This information is limited to blood
compartment changes. The interstitial space, which is
mostly sodium-dependent, is better estimated by clinical
assessment of edema or body weight [54, 55]. Rarely bed
scales are used to assess more precisely the weight
changes over a dialysis session.
For most infants and children weighing less than 10 kg
the need for more than three sessions a week may become
evident to enable adapted nutrition, i.e. milk that is ”wa-
ter”, hence 4 to 5 sessions a week are frequently pre-
scribed [3, 11]. The adequate number and duration of
each session should avoid partial fasting to achieve the
weight needed to facilitate a short dialysis duration [7, 21,
80]. The volume of fluid used for extracorporeal blood
replacement at the end of the session should be limited,
and preferably a glucose solution instead of saline solu-
tion be used, especially in infants without residual renal
function [3].
At the beginning of the dialysis session clinical man-
ifestations of bioincompatibility may occur. This first use
reaction is related to the biocompatibility of the material
in the extracorporeal circuit, i.e. membrane, lines or even
the needle either during the first session, first contact with
the “extracorporeal” material or thereafter for example, in
a new dialysis center for holidays. The major positive
diagnostic criteria is the onset within 20 min of starting
dialysis, of the major symptoms of dyspnea, burning heat
throughout the body or access site, angioedema, flushing
or vascular collapse, or with minor symptoms such as
Table 6 Hemodialysis prescription for children: adequate, before optimum
- Dialysis modality should enable achievement of blood pressure control (without antihypertensive medications for most children),
normal myocardial morphology and function
- Dialysis dose prescription should not only be an urea dialysis dose. Removal of the other uremic toxins should be considered, not
only middle molecules but overall phosphate
- Dialysis frequency and duration must be adjusted to the tolerance of ultrafiltration to reach the dry weight. Ultrafiltration rate should
not exceed 1.5€0.5% of body weight per hour (in theory no more than 5% BW loss per whole session). Blood volume (hematocrite)
guided ultrafiltration secure
- A regular diet survey is essential to maintain adequate protein and calorie intakes. Urea kinetic assessment enables not only urea
dialysis dose calculation, i.e. Kt/V, but also estimation of protein intake by use of the PCRn calculation (protein catabolic rate). Fasting
to enable a short duration three times a week dialysis schedule is inadequate care management
- Too fast ultrafiltration can induce hypotension and cramps during dialysis, usually during the second half time session, and fatigue
and/or hang over after dialysis
- A small solute, e.g. urea, clearance which is too high is a factor of disequilibrium syndrome occurring during dialysis, usually after
the first half/or one hour session time with headache, even seizures, nausea, vomiting, sleepiness or a hypertensive tendency with
a narrow range between systolic and diastolic pressure values. Symptoms usually disappear a few hours after the end of the dialysis
1063itching, rhinorrhea, lacrymation, urticaria, or abdominal
cramping. Even if its occurrence is rare, or underesti-
mated in the event of intermittent minor symptoms only
during the first hour of session, the risk could be sub-
stantial. Biocompatible membranes, steam-sterilized ma-
terial, adequate flushing of the circuit before blood con-
nection, are some of the most important prevention fac-
tors [32].
The dialysis per se should be regarded as part of an
overall strategy for care including dietary adequacy and
interdialytic therapy [1, 21]. A weight gain over 10% dry
BW during the interval of two sessions is often correlated
with global non-compliance [3, 80]. In these cases, major
outcomes could even occur: first acute, i.e. hyperkalemia
or pulmonary edema, second chronic, i.e. hyperparathy-
roidism, and third long term, i.e. cardiovascular and
coronary involvement [44, 45].
Conclusions
Hemodialysis in children has benefited from major pro-
gress over the last 20 years. The morbidity of the sessions
has decreased, even disappeared, seizures being excep-
tional, hypotensive episodes or headaches rare, and pain
related to the fistula puncture effectively prevented by
xylocaine ointment. The development of urea kinetic
modeling enables calculation of the dialysis dose and
indirect assessment of protein intake, nPCR. Even if the
validity of these values is questioned their combined
analysis provides an assessment and therefore is a “good
thing”. The patient also benefits from the technological
revolution. The newer machines enable precise control of
ultrafiltration volumetric assessment and continuous
blood volume monitoring during the session, buffered
bicarbonate has become a standard technique, synthetic
more biocompatible membranes and specific material
available for babies/infants have been developed. Non
invasive intervention, for example blood volume guided
ultrafiltration have provided more adequate dialysis ses-
sions and better dry weight assessment [81]. Last, the
availability of erythropoietin [82] and of growth hormone
and the promising results from enhanced dialysis dose on
both growth and cardiac function [13, 20], all give the
dialyzed child a real increased quality of life. In theory,
reduction of dialysis prescription to only a urea dialysis
dose achieved by three short (3-h) dialysis sessions,
should be abandoned for long term dialyzed children and
replaced by optimum dialysis obtained with longer (4 and
more hours) and/or more frequent (daily: 5 to 6) ses-
sions [13, 20, 79, 80]. But for such a daily dialysis
strategy all the costs must be considered. On the one hand
the financial cost cannot be neglected. For the patient
bearing the burden, on the other hand, such an intensive
dialysis prescription is acceptable only as an integrated
therapy life project, a dialysis–transplantation program
(HD, PD) with special regard for prevention of the vas-
cular calcification [83]. Daily hemodialysis is one ap-
proach, perhaps the only one, to achieve phosphate pu-
rification [16, 17, 18, 19] and thereby maintain the cal-
cium phosphorus product in the optimum range of 3.3 to
4.4 mmol
2 mL
 2 [43].
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